40 results on '"Lamprianidou E"'
Search Results
2. Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME
3. The effectiveness of stabilising exercises in pelvic girdle pain during pregnancy and after delivery: A systematic review
4. Firing patterns in a random network cellular automata model of the brain
5. P101 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME
6. P082 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: SYSTEMATIC ANALYSIS OF T LYMPHOCYTES IN MYELOID NEOPLASMS
7. P742: TRANSCRIPTOMIC ANALYSIS OF ISOLATED CD4+ AND CD8+ T CELLS REVEALS DIFFERENCES IN TCR REPERTOIRE IN PATIENTS WITH HIGH RISK MDS COMPARED TO AML.
8. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine—data from the Hellenic myelodysplastic syndrome study group
9. Modulation of IL-6/STAT3 signaling axis in CD41FOXP32 T cells represents a potential antitumor mechanism of azacitidine
10. THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH-RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME
11. PS1328 ABNORMAL LEVELS OF FUNCTIONAL CTLS ON HIGH RISK MDS PATIENTS UNDER AZACYTIDINE TREATMENT
12. PF537 THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH-RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME
13. PS1334 THERAPEUTIC RESPONSE OF MYELODYSPLASTIC SYNDROMES TO EPIGENETIC DRUGS INDEPENDENTLY OF ENDOGENOUS RETROELEMENT MODULATION
14. The effectiveness of stabilising exercises in pelvic girdle pain during pregnancy and after delivery: A systematic review
15. The Stat3/5 signaling biosignature in hematopoietic stem/progenitor cells predicts response and outcome in myelodysplastic syndrome patients treated with azacitidine
16. Potentially probioticLactobacillusstrains with anti-proliferative activity induce cytokine/chemokine production and neutrophil recruitment in mice
17. AZACYTIDINE UPREGULATES PERFORIN EXPRESSION IN CYTOTOXIC T AND NATURAL KILLER CELLS OF RESPONDING PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
18. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine
19. Signal Transducer and Activator of Transcription (STAT) signaling b profile at the single cell level: Novel insights in the association of FOXP3+ T regulatory cells with recurrent spontaneous abortions before and after lymphocyte immunotherapy (LIT)
20. Distinct epigenetic modulation of signal transducer and activator of transcription (STAT) signaling in FOXP3+T regulatory cells of CMML-2 patients
21. 283 AZACYTIDINE UPREGULATES PERFORIN EXPRESSION IN CYTOTOXIC T AND NATURAL KILLER CELLS OF RESPONDING PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
22. Potentially probiotic Lactobacillus strains with anti-proliferative activity induce cytokine/chemokine production and neutrophil recruitment in mice.
23. P-244 Distinct epigenetic modulation of signal transducer and activator of transcription (STAT) signaling in FOXP3+ T regulatory cells of CMML-2 patients
24. Potentially probiotic Lactobacillusstrains with anti-proliferative activity induce cytokine/chemokine production and neutrophil recruitment in mice
25. Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes.
26. MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
27. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
28. Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter.
29. Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine.
30. Immune Responses Raised in an Experimental Colon Carcinoma Model Following Oral Administration of Lactobacillus casei .
31. The STAT signaling profile at the single cell level reveals novel insights in the association of FOXP3+ T regulatory cells with recurrent spontaneous abortions before and after lymphocyte immunotherapy.
32. Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.
33. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
34. Isothiocyanate-induced Cell Cycle Arrest in a Novel In Vitro Exposure Protocol of Human Malignant Melanoma (A375) Cells.
35. Improving the Subcutaneous Mouse Tumor Model by Effective Manipulation of Magnetic Nanoparticles-Treated Implanted Cancer Cells.
36. Myeloid Neoplasms with Isolated Isochromosome 17q: a yet to be Defined Entity.
37. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
38. Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms.
39. Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients.
40. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.